Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMAB8LH)

• Drug Name: Tildacerfont Drug Info
• Synonyms: Tildacerfont; 1014983-00-6; 4-(4-chloro-5-(2,5-dimethyl-7-(pentan-3-yl)pyrazolo[1,5-a]pyrimidin-3-yl)thiazol-2-yl)morpholine; SCHEMBL2182127; XVAWSBAQNIXMIO-UHFFFAOYSA-N; AKOS040747540; MS-27364; HY-113603; 3-(4-Chloro-2-morpholin-4-yl-thiazol-5-yl)-7-(1-ethyl-propyl)-2,5-dimethyl-pyrazolo[1,5-a]pyrimidine; 4-[4-chloro-5-(2,5-dimethyl-7-pentan-3-ylpyrazolo[1,5-a]pyrimidin-3-yl)-1,3-thiazol-2-yl]morpholine; 7-(1-ethyl-propyl)-3-(4-chloro-2-morpholin-4-yl-thiazol-5-yl)-2,5-dimethyl-pyrazolo[1,5-a]pyrimidine

Indication

Disease Entry	ICD 11	Status	REF
Congenital adrenal hyperplasia	5A71.01	Phase 2	[1]

• Cross-matching ID:
  PubChem CID: 24898977
  TTD Drug ID: DMAB8LH

Molecule(s) Related to This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Corticotropin-releasing factor receptor 1 (CRHR1)	TT7EFHR	CRFR1_HUMAN	Antagonist	[2]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule	Molecule Type	Gene Name	Liver	Colon	Kidney	Small Intestine
Corticotropin-releasing factor receptor 1 (CRHR1)	DTT	CRHR1	5.3	3.755	5.206	3.926

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

• The Studied Disease: Congenital adrenal hyperplasia
• ICD Disease Classification: 5A71.01

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Corticotropin-releasing factor receptor 1 (CRHR1)	DTT	CRHR1	7.70E-01	-0.02	-0.1

References

• [1] ClinicalTrials.gov (NCT05370521) A Randomized, Placebo-Controlled, Dose Escalation Study to Evaluate the Safety and Efficacy of Tildacerfont in Adult Subjects With Polycystic Ovary Syndrome (PCOS) and Elevated Adrenal Androgens. U.S.National Institutes of Health.
• [2] Clinical advances in the pharmacotherapy of congenital adrenal hyperplasia. Eur J Endocrinol. 2021 Nov 30;186(1):R1-R14.